ScholarIQanswers from OpenAlex & ORCID
Diamant Thaçi
ResearcherPublications, citations & collaboration network
Diamant Thaçi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Diamant Thaçi have?
ScholarIQindexed works
Diamant Thaçi has 707 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Diamant Thaçi have?
ScholarIQcitation count
Diamant Thaçi has 23,742 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Diamant Thaçi?
ScholarIQh-index
Diamant Thaçi has an h-index of 73 in OpenAlex.
What is the i10-index of Diamant Thaçi?
ScholarIQi10-index
Diamant Thaçi has an i10-index of 252 in OpenAlex.
What is the ORCID of Diamant Thaçi?
ScholarIQorcid
The ORCID for Diamant Thaçi is on the source record.
What is the OpenAlex record for Diamant Thaçi?
ScholarIQopenalex
The OpenAlex for Diamant Thaçi is on the source record.
What are the most-cited papers on Diamant Thaçi?
ScholarIQmost cited works
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck, Diamant Thaçi, Jennifer D. Hamilton, Neil M.H. Graham, Thomas Bieber, Ross E. Rocklin, Jeffrey E. Ming, Haobo Ren, Richard Kao, Eric L. Simpson, Marius Ardeleanu, Steven P. Weinstein, Gianluca Pirozzi, Emma Guttman‐Yassky, Mayte Suárez‐Fariñas, Melissa Hager, Neil Stahl, George D. Yancopoulos, Allen Radin
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Diamant Thaçi, Eric L. Simpson, Lisa A. Beck, Thomas Bieber, Andrew Blauvelt, Kim Papp, Weily Soong, Margitta Worm, Jacek C. Szepietowski, Howard Sofen, Makoto Kawashima, Richard Wu, Steven P. Weinstein, Neil M.H. Graham, Gianluca Pirozzi, Ariel Teper, E. Rand Sutherland, Vera Mastey, Neil Stahl, George D. Yancopoulos, Marius Ardeleanu
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson, Kim Papp, Aileen L. Pangan, Andrew Blauvelt, Diamant Thaçi, Chia‐Yu Chu, Hyuck-Ki Hong, Norito Katoh, Amy S. Paller, Brian Calimlim, Yihua Gu, Xiaofei Hu, Meng Liu, Yang Yang, John Liu, Allan R. Tenorio, Alvina D. Chu, Alan D. Irvine
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich, Kim Papp, Andrew Blauvelt, Stephen K. Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, N. Cichanowitz, Qing Li, Kenneth Liu, Carmen La Rosa, Stuart Green, Alexa B. Kimball
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
Marjolein de Bruin‐Weller, Diamant Thaçi, Catherine Smith, Kristian Reich, Michael J. Cork, Allen Radin, Q. Zhang, Bolanle Akinlade, A. Gadkari, Laurent Eckert, Thomas Hultsch, Z. Chen, Gianluca Pirozzi, Neil M.H. Graham, Brad Shumel